Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune‐mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital‐based claims database
Hiroshi Tsushima, Nobuyuki Yajima, Takashi Nomiyama, Ryoko Sakai, Hisashi Noma, Akira Katagiri, Naoto Tamura · 2026
Read Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune‐mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital‐based claims database by Hiroshi Tsushima, Nobuyuki Yajima, Takashi Nomiyama, Ryoko Sakai, Hisashi Noma, Akira Katagiri, Naoto Tamura (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13398639.txt.
Description
Hiroshi Tsushima and colleagues tested whether a diabetes drug class raises urinary infection risk in people with immune-mediated inflammatory disease. Their 2026 study emulates a trial using Japanese hospital claims from 2014 to 2024, comparing new users of SGLT2 inhibitors with new users of metformin. SGLT2 drugs lower blood sugar by spilling glucose into urine, raising a plausible infection concern, especially under immune suppression.
Among 1,845 SGLT2 starters and 1,499 metformin starters, the SGLT2 group showed no significant increase in urinary tract infection or upper urinary infection, and results held across immune-suppressing drug groups. Genital infection risk, however, was higher with SGLT2 drugs. The paper reassures prescribers about urinary infection in this population while flagging genital infection counseling, with claims data limits noted.
Catalog record
| CREATOR | Hiroshi Tsushima, Nobuyuki Yajima, Takashi Nomiyama, Ryoko Sakai, Hisashi Noma, Akira Katagiri, Naoto Tamura |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |